Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Conditions

Advanced Cancer

Brief summary

Molecular Tumor Board at the Center for Personalized Medicine

Detailed description

Molecular Tumor Board at the Center for Personalized Medicine The study objectives are * To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care * To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) * To prospectively assess patient-reported outcome of MTB patients * To evaluate compliance to MTB suggestions in routine clinical care

David Rieger, H. D. Becker, Barbara Walter, Lorenz Doerner, Stephan Kurz et al. (21 authors)

Neuro-Oncology2025-10-01

10.1093/neuonc/noaf193.224

Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework

Sylvia C. Kurz, Mirjam Renovanz, Michael Bitzer, Maximilian Niyazi, Nisar P. Malek et al. (7 authors)

Neuro-Oncology Advances2025-01-01

10.1093/noajnl/vdaf127

NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS

Sylvia C. Kurz, Mirjam Renovanz, Johannes Rieger, Paula Bombach, Lucia Grosse et al. (17 authors)

Neuro-Oncology2023-11-011 citations

10.1093/neuonc/noad179.0842

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Mirjam Renovanz, Sylvia C. Kurz, Johannes Rieger, Bianca Walter, Hannes Becker et al. (50 authors)

Neuro-Oncology Advances2023-01-0117 citations

10.1093/noajnl/vdad012

Interventions

OTHERno intervention

observational study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Given informed consent (broad consent of the University Hospital Tübingen) * ≥ 18 years of age * Clinical indication for a referral to Molecular Tumor Board by the treating physician

Exclusion criteria

* The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival	6 months	Progression-free survival

Secondary

Measure	Time frame	Description
Overall survival	an average of 1 year	Progression-free survival

Countries

Germany

Contacts

Primary ContactGhazaleh Tabatabai, Prof

ghazaleh.tabatabai@med.uni-tuebingen.de0049707129

Backup ContactNisar P Malek, Prof